This report describes the current distribution and funding mix for naloxone access and explores the potential impacts of policy changes to expand coverage for naloxone as a non-prescription product. It argues that non-prescription status for naloxone and education about its efficacy and availability would help reduce opioid overdose deaths in the US.
Resource Type
Peer-reviewed Articles and Reports
Continuum of Care
Harm Reduction
Response Approach
Overdose prevention
Post-overdose response